Metabolix Names Heike Sederoff, Ph.D. to Yield10 Bioscience

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Metabolix Names Heike Sederoff, Ph.D. to Yield10 Bioscience Scientific Advisory Board

WOBURN, Mass., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ: MBLX ), today announced that Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University (“NC State”) has been named to the Yield10 Bioscience Scientific Advisory Board (“SAB”).  Yield10 Bioscience, the crop science venture launched by Metabolix in 2015, is focused on developing proprietary, breakthrough technologies to create step-changes in yield for major food and feed crops to enhance global food security.

“We are pleased to welcome Dr. Sederoff to our Scientific Advisory Board,” said Oliver Peoples, Ph.D., chief scientific officer. “We have collaborated with Dr. Sederoff and her team at NC State on advanced metabolic engineering technologies for improving crop yield using camelina as a model system. We look forward to Heike’s contributions in her role as an advisor to our team as we work in 2016 to translate our approach to boosting crop yield and drought resistance to agriculturally significant crops and move from greenhouse to field trials.”

“We have collaborated with the Yield10 team on grants supporting advanced research to improve seed and biomass yield in oilseed crops,” said Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University. “Our work focused on yield improvement using camelina has produced encouraging results and we look forward to continue working with the Yield10 team to engineer new plant yield traits applicable to important feed and food crops.”

Heike Sederoff, Ph.D. is currently Professor in the Department of Plant and Molecular Biology and Systems and Synthetic Biology Chair at North Carolina State University. Dr. Sederoff’s recent research has focused on the study of plant systems and synthetic biology. She has used metabolic engineering methods to increase carbon assimilation and allocation in an oilseed crop and in model plant species including marine algae. Dr. Sederoff received an M.S. in Biochemistry and a Ph.D. in Plant Biochemistry at University of Göttingen, Germany.

Earlier in 2016, Yield10 Bioscience named Michael Lassner, Ph.D., former vice president of trait discovery at Dupont Pioneer and Danny Schnell, Ph.D., Professor and Chair of the Department of Plant Biology at Michigan State University, to its SAB.  

About Metabolix 

Metabolix, Inc. is implementing a strategic plan under which the Company has wound down its legacy PHA biopolymer business and Yield10 Bioscience will become its core business with a focus on developing disruptive technologies for step-change improvements in crop yield. Yield10 is leveraging Metabolix’s extensive track record of innovation based around optimizing the flow of carbon intermediates in living systems. Yield10 is working on new approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is advancing several yield traits in development in crops such as camelina, canola, soybean and corn. The Company is based in Woburn, MA.   

For more information, visit www.metabolix.com . (MBLX-G)

For more information on Yield10 Bioscience, visit Yield10 .

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding the progress of Yield10, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Metabolix Contact: Lynne H. Brum, 617-682-4693, LBrum@metabolix.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 124

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 90

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 110

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 205

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 162

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 202

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 218

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading

Top 5 Most Recently Viewed Articles

Grand Circle Cruise Line Achieves Top Honors for 2025 Travel

Updated Category News Views 271

Grand Circle Cruise Line Recognized Among the Best Grand Circle Cruise Line (GCCL) recently earned the impressive title of #2 Best River Cruise Line in the Travel + Leisure's 2025 World's Best Awards. This accolade showcases the hard work and dedication of the teams and crew members who make each journey remarkable along Europe’s scenic rivers. Celebrating a Special...

Continue Reading
Lancaster Resources Achieves License Approval for Gold Project Exploration

Updated Category News Views 145

Lancaster Resources Secures Approval for Exploration License Vancouver-based Lancaster Resources Inc. (CSE:LCR) (OTC:LANRF) (FRA:6UF0) is pleased to announce a significant milestone in its gold exploration journey. The company has received confirmation of an Exploration License for the Lake Cargelligo Gold Project from the State of New South Wales. Covering an impressive...

Continue Reading
Future of Vitrectomy Devices: Growth Insights and Trends

Updated Category News Views 93

Understanding the Vitrectomy Devices Market Growth The vitrectomy devices industry has become increasingly vital in treating various eye-related disorders, with significant growth projected in the coming years. By focusing on technological advancements and heightened awareness of eye health, the market is set to expand impressively. According to a recent report, the...

Continue Reading
Exploring RDG Mining's Innovative Cloud Mining Solution

Updated Category News Views 158

Understanding RDG Mining's Latest Offerings In recent times, the popularity of cryptocurrency has surged significantly, with platforms like RDG Mining capitalizing on this trend. RDG Mining is a leading cloud mining service based in the UK that has captured the interest of over 7.5 million users globally, particularly with the rise in various cryptocurrencies, including...

Continue Reading
Pharma Equity Group Updates Its Financial Reporting Strategy

Updated Category News Views 82

Revisions to Financial Reporting and Calendar The board of Pharma Equity Group A/S has recently made the strategic decision to submit only half-yearly financial reports moving forward. This adjustment reflects a shift in focus towards more impactful reporting. As a result, the financial calendar for 2025 has been updated to better align with these new reporting practices....

Continue Reading